Evidence map›Paper›PMID 26107496›Full record

ArticlePloS one2015

Species-Specific Chromosome Engineering Greatly Improves Fully Human Polyclonal Antibody Production Profile in Cattle.

Hiroaki Matsushita, Akiko Sano, Hua Wu, Zhongde Wang, Jin-An Jiao, Poothappillai Kasinathan, Eddie J Sullivan, Yoshimi Kuroiwa

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Use of Genome Editing Techniques to Produce Transgenic Farm Animals.Advances in experimental medicine and biology · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Frontiers in immunology · 2019
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Hiroaki MatsushitaSAB Biotherapeutics, Inc., Sioux Falls, South Dakota, United States of America; Hematech, Inc., Sioux Falls, South Dakota, United States of America.
Akiko SanoKyowa Hakko Kirin, Co., Ltd., Chiyoda-ku, Tokyo, Japan; Hematech, Inc., Sioux Falls, South Dakota, United States of America.
Hua WuSAB Biotherapeutics, Inc., Sioux Falls, South Dakota, United States of America; Hematech, Inc., Sioux Falls, South Dakota, United States of America.
Zhongde WangDepartment of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah, United States of America; Hematech, Inc., Sioux Falls, South Dakota, United States of America.
Jin-An JiaoSAB Biotherapeutics, Inc., Sioux Falls, South Dakota, United States of America; Hematech, Inc., Sioux Falls, South Dakota, United States of America.
Poothappillai KasinathanTrans Ova Genetics, Sioux Center, Iowa, United States of America; Hematech, Inc., Sioux Falls, South Dakota, United States of America.
Eddie J SullivanSAB Biotherapeutics, Inc., Sioux Falls, South Dakota, United States of America; Hematech, Inc., Sioux Falls, South Dakota, United States of America.
Yoshimi KuroiwaKyowa Hakko Kirin, Co., Ltd., Chiyoda-ku, Tokyo, Japan; Hematech, Inc., Sioux Falls, South Dakota, United States of America.
University of Sioux Falls · USSab Biotherapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Large-scale production of fully human IgG (hIgG) or human polyclonal antibodies (hpAbs) by transgenic animals could be useful for human therapy. However, production level of hpAbs in transgenic animals is generally very low, probably due to the fact that evolutionarily unique interspecies-incompatible genomic sequences between human and non-human host species may impede high production of fully hIgG in the non-human environment. To address this issue, we performed species-specific human artificial chromosome (HAC) engineering and tested these engineered HAC in cattle. Our previous study has demonstrated that site-specific genomic chimerization of pre-B cell receptor/B cell receptor (pre-BCR/BCR) components on HAC vectors significantly improves human IgG expression in cattle where the endogenous bovine immunoglobulin genes were knocked out. In this report, hIgG1 class switch regulatory elements were subjected to site-specific genomic chimerization on HAC vectors to further enhance hIgG expression and improve hIgG subclass distribution in cattle. These species-specific modifications in a chromosome scale resulted in much higher production levels of fully hIgG of up to 15 g/L in sera or plasma, the highest ever reported for a transgenic animal system. Transchromosomic (Tc) cattle containing engineered HAC vectors generated hpAbs with high titers against human-origin antigens following immunization. This study clearly demonstrates that species-specific sequence differences in pre-BCR/BCR components and IgG1 class switch regulatory elements between human and bovine are indeed functionally distinct across the two species, and therefore, are responsible for low production of fully hIgG in our early versions of Tc cattle. The high production levels of fully hIgG with hIgG1 subclass dominancy in a large farm animal species achieved here is an important milestone towards broad therapeutic applications of hpAbs.

Indexed as

AnimalsAnimals, Genetically ModifiedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntigensCattleCell Line, TumorChickensChromosome MappingChromosomes, Artificial, HumanGene Knockout TechniquesGenetic EngineeringGenetic VectorsHumansImmunizationImmunoglobulin GAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntigensImmunoglobulin GPre-B Cell Receptors

Identifiers

PMID26107496
PMCPMC4479556
OpenAlexW2340041849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.